

MusclePharm Corp  
Form 8-K  
July 19, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 14, 2011

MUSCLEPHARM CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

|   |                                       |   |
|---|---------------------------------------|---|
| Nevada<br>(State or other jurisdiction<br>of incorporation) | 000-53166<br>(Commission File Number) | 77-0664193<br>(I.R.S. Employer<br>Identification) |
|---|---------------------------------------|---|

4721 Ironton Street  
Denver, Colorado 80239  
(Address of Principal Executive Offices)

(303) 396-6100  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On July 14, 2011, the Company issued a press release reporting their preliminary financial results for the second quarter ended June 30, 2011. The press release has been attached hereto as an exhibit and will also be posted on the Company's website: [www.musclepharm.com](http://www.musclepharm.com).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description

No.

99.1 Press Release, dated July 14, 2011

---

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MUSCLEPHARM CORPORATION

Date: July 14, 2011

By: /s/ Brad J. Pyatt  
Name: Brad J. Pyatt  
Title: Chief Executive  
Officer